BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dissegna D, Sponza M, Falleti E, Fabris C, Vit A, Angeli P, Piano S, Cussigh A, Cmet S, Toniutto P. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2019;31:626-632. [PMID: 30550458 DOI: 10.1097/meg.0000000000001342] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Jeyanesan D, Balachandrakumar VK, Hogan B. Guideline review: transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension—a BSG guideline. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2022-102151] [Reference Citation Analysis]
2 Will V, Rodrigues SG, Berzigotti A. Current treatment options of refractory ascites in liver cirrhosis - A systematic review and meta-analysis. Dig Liver Dis 2022:S1590-8658(21)00894-X. [PMID: 35016859 DOI: 10.1016/j.dld.2021.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Rêgo HMC, Medronha EF, Junior EZ, Tovo CV, de Mattos AA. Transjugular intrahepatic portosystemic shunt with transhepatic portal vein puncture guided by ultrasound: a technical alternative. Eur J Gastroenterol Hepatol 2022;34:112-6. [PMID: 34748302 DOI: 10.1097/MEG.0000000000002174] [Reference Citation Analysis]
4 Bellouhou F, Haddar FE, Errami AA, Sofia Oubaha SO, Samlani Z, Krati K. Portal hypertension: monocentric retrospective study of 387 cases and review of the literature. GHOA 2021;12:167-171. [DOI: 10.15406/ghoa.2021.12.00480] [Reference Citation Analysis]
5 de Wit K, Schaapman JJ, Nevens F, Verbeek J, Coenen S, Cuperus FJC, Kramer M, Tjwa ETTL, Mostafavi N, Dijkgraaf MGW, van Delden OM, Beuers UHW, Coenraad MJ, Takkenberg RB. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial). BMJ Open Gastroenterol 2020;7:e000531. [PMID: 33372103 DOI: 10.1136/bmjgast-2020-000531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Will V, Rodrigues SG, Stirnimann G, Gottardi A, Bosch J, Berzigotti A. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications. United European Gastroenterol J 2020;8:961-9. [PMID: 32588789 DOI: 10.1177/2050640620938525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Santos S, Dantas E, Veloso Gomes F, Luz JH, Vasco Costa N, Bilhim T, Calinas F, Martins A, Coimbra É. Retrospective Study of Transjugular Intrahepatic Portosystemic Shunt Placement for Cirrhotic Portal Hypertension. GE Port J Gastroenterol 2020;28:5-12. [PMID: 33564700 DOI: 10.1159/000507894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Bucher JN, Hollenbach M, Strocka S, Gaebelein G, Moche M, Kaiser T, Bartels M, Hoffmeister A. Segmental intrahepatic cholestasis as a technical complication of the transjugular intrahepatic porto-systemic shunt. World J Gastroenterol 2019; 25(43): 6430-6439 [PMID: 31798279 DOI: 10.3748/wjg.v25.i43.6430] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]